Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
22:517–520 © 1999 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 22, 1999

Author Index

Abdala N, 194
Abel S, 401
Abramowsky C, 379
Adorni F, 101
Ahnn S, 49
Ährlund-Richter L, 445
Ait-Khaled M, 139
Alberici F, 65
Aledort LM, 75
Alston B, 348
Anastos K, 124
Anderson KT, 194
Andrade T, 288
Angel JB, 209
ANRS-048 IL-2 Study Group, 31
Arnó A, 132
Arribas JR, 308
Asch SM, 490
Astiz M, 155

Bailey RC, 294
Bain BJ, 92
Balagué M, 132
Balducci M, 65
Bandrés JC, 413
Banfi MC, 461
Bangham CRM, 92
Bánhegyi D, 311
Barchi E, 461
Barkan SE, 312
Bartsch G, 253
Beall G, 39
Beeler JA, 75
Bell DC, 280
Benjamin G, 272
Bentham WDL, 503
Bera O, 401
Beyrer C, 180
Biberfeld P, 364
Blanche S, 267
Blatt PM, 75
Blaxhult A, 369
Bollinger RC, 19
Bongertz V, 288
Böni J, 174
Bonjoch A, 132
Bosco O, 461
Bouchet L, 31
Boukef K, 314
Branson BM, 395
Brites C, 288
Britton S, 445
Brookmeyer RS, 19
Bucciardini R, 260
Buck WR, 10
Burckhardt JJ, 174
Burgard M, 267
Bürgisser P, 174
Burke M, 467
Busch MP, 484

Cabié A, 401
Cadden J, 155
Cai L, 503
Caldeira E, 272
Caliendo AM, 208
Campbell TB, 333
Cao H, 208
Capitant C, 31
Carlos MP, 317
Carr A, 437
Carrington M, 75
Cassone A, 106
Cauda R, 106
Cejtin HE, 247
Césaire R, 401
Chan J, 209
Chan LS, 124
Chandra A, 364
Chandra P, 364
Chang KH, 409
Chapman TF, 83
Chen J, 180
Choi JM, 409
Choi YH, 409
Chou T-C, 430
Christen L, 56
Christen S, 56
Chun Chen Z, 124
Church JA, 309
Citterio P, 101
Clark R, 408
Clark RA, 189
Clatts MC, 194
Clotet B, 132
Clumeck N, 369
Cohen AR, 75
Cohen MR, 56
Cohen RA, 395
Cohen V, 358
Collins G, 253
Conant M, 235
Cone R, 56
Cooper DA, 437
Couto-Fernandez JC, 288
Cross AP, 39
Cryz SJ Jr, 467
Csiszár A, 311
Cunningham P, 437
Currier JS, 189

Daenke S, 92
d'Arminio-Monforte A, 101
Dascomb K, 408
Davis R, 92
De Clercq E, 107
De Vroey V, 107
Dean M, 75
DeCristofaro K, 49
Del Borgo C, 461
Delfraissy J-F, 228
Delfraissy JF, 267
Demirhan I, 364
Denisi R, 103
Des Jarlais DC, 83
Desmyter J, 107
Devers J, 19
di Gennaro G, 407
Díaz-Mitoma F, 317
Dickinson BP, 161
Dickinson G, 358
Didier ES, 408
Dilley J, 484
DiMichele D, 75
Division of AIDS Treatment Research Initiative (DATRI) 022 Study Group, 348
Dorrucci M, 65
Dorsky DI, 213
Dos Santos G, 401
Duchin JS, 312
Dunkle LM, 39
Durand-Gasselin I, 31

Eisenberger-Matityahu D, 247
Eizuru Y, 200
Eldred L, 272
Ellenberg JH, 348
Emlie D, 31
Erb P, 174
Ernst JA, 498
Eyster ME, 75

Fantoni M, 461
Ferrando SJ, 146
Fierz W, 174
Finberg RW, 1
Fitzpatrick L, 333
Flanigan TP, 161
Fleming PL, 71
Fletcher MA, 358
Flynn C, 272
Foussat A, 31
Fox S, 309
Fragola V, 260
Frau E, 228
Frazer T, 408
Freeman LM, 119
French N, 509
Friedman SR, 83
Friedman-Kien AE, 235
Frost RA, 49
Fugger L, 325
Fuhrer J, 49
Furlan V, 228

Galanaud P, 31
Galazzi M, 101
Galli M, 101
Gallo TM, 194
Galvão-Castro B, 288
Ganea CE, 498
García-Samaniego J, 308
Garlick PJ, 49
Gatell J, 369
Gathe J, 39
Gebhardt M, 174
Gelato MC, 49
Gerstoft J, 325
Gianotto M, 101
Gibert CL, 253
Gilks CF, 509
Goebel F-D, 369
Goedert JJ, 75
Goldberg B, 105
Goldsamt LA, 194
Goldstein H, 467
Gomperts E, 309
González J, 308
Gorbach SL, 119
Gotch F, 167
Gottle R, 19
Goujard C, 228
Graham NMH, 386
Grassini A, 101
Gray RH, 379
Greaves W, 348
Griffin P, 139
Grob P, 174
Gu J, 180
Gurri-Glass G, 180

Hackett J Jr, 221
Hall S, 92
Hardy D, 39
Harrer T, 107
Harrigan PR, 260
Harrington RD, 213
Hasselmayer O, 364
Hasui K, 200
Haszlett P, 341
Hawksworth D, 221
Hayes KA, 10
Hazen R, 406
Heimer R, 194
Heredia A, 406
Hermans P, 107
Hickman RK, 221
Hirsch MS, 430
Hisada M, 302
Hmida S, 314
Hoffer LD, 194
Holmberg SD, 498
Hom D, 208
Hon H, 19
Hopkins SG, 312
Horváth A, 311
Hotchkiss G, 445

INCAS Study Team, 260
Irwin KL, 498
Isashiki Y, 200
Iversen AKN, 325
Izopet J, 103
Izumo S, 200
Izzi I, 461

Janoff EN, 509
Janssen RS, 484
Johnson AM, 369
Johnson JL, 208
Johnson M, 19
Jordan J, 1
Jou A, 132
Joyce CRB, 56
Juzbasic S, 407

Kaabi H, 314
Kaleebu P, 167
Kang SM, 409
Kanki PJ, 208
Kashamuka M, 19
Kassler WJ, 395
Katsuta K, 200
Katz MH, 484
Katzenstein DA, 341
Kaufmann GR, 437
Kellogg TA, 484
Kessler CM, 75
Kim JM, 409
Kislak JW, 155
Kissinger P, 408
Kleim J-P, 139
Klevens RM, 71
Klimas N, 358
Komaroff E, 247
Konkle B, 75
Kopicko JJ, 408
Korn A, 247
Kovacs A, 124
Kravcik S, 209
Kumi J, 348
Kundu S, 341
Kurtagic S, 101
Kyriakides T, 194

La Seta-Catamancio S, 101
Labetoulle M, 228
Lackner AA, 119
Lai S, 180
Lang CH, 49
Lantz O, 228
Larsson S, 445
Law M, 437
Lawrence J, 1
Lazzarin A, 369
Le N, 406
Learn GH, 325
Lecointe D, 228
Ledergerber B, 56
Lederman HM, 19
Ledermann U, 56
Leissinger C, 75
Lenz J, 467
Leonetti AM, 312
Levine AM, 124
Levy Y, 31
Lew DJ, 409
Li C, 379
Li J, 71
Liang S, 180
Lin R, 155
Liu B, 180
Liu G-Q, 467
Liu W, 180
Lobato MN, 71
Long A, 490
Loy M, 56
Lubaki NM, 19
Luban N, 75
Luciano PA, 194
Lundgren JD, 369
Lüthy R, 56
Lyles RH, 386

Maamar M, 314
Macalino G, 161
Madans M, 253
Madge S, 369
Maggio CM, 358

Maggiolo F, 453
Maher K, 358
Malamba S, 167
Mani I, 208
Mannick JB, 1
Mansfield KG, 119
Margolick JB, 386
Margolis D, 406
Maródi CL, 311
Martín JC, 413
Martinez A, 348
Maruyama K, 10
Maserati R, 453
Massad LS, 247
Massip P, 103
Mathes LE, 10
Matsuoka E, 200
Matter L, 174
Matutes E, 92
MaWhinney S, 333
Mayaux M-J, 267
McFarland W, 484
McGowan JP, 498
McNurlan MA, 49
Mellors JW, 386
Melosky B, 235
Merigan TC, 341
Merrill DP, 430
Meyer WA III, 124
Milazzo L, 101
Mildvan D, 189
Miller LG, 490
Miller M, 210
Miller ME, 490
Minder E, 174
Misrahi M, 267
Mizrachi Y, 467
Mmiro FA, 379
Mocroft A, 369
Mojaat N, 314
Montaner JSG, 260
Morgado MG, 288
Morgan D, 167
Moritoyo T, 200
Moroni M, 101
Muderspach L, 124
Mueller NE, 302
Mugerwa RD, 208
Mujugira A, 509
Mulder D, 509
Mullins JI, 325
Murphy RL, 39
Murri R, 461
Muth K, 348
Muurahainen N, 253
Mynarcik DC, 49

Nagai M, 200
Nagy K, 311
Nakiyingi J, 509
Nasti G, 407
Naumova EN, 119
Ndugwa C, 379
Neema S, 294
Negredo E, 132
N'Go N, 267
Nguyên GT, 75
Niessen F, 228
Northfelt DW, 235

O'Brien SJ, 75
O'Brien TR, 75
Offret H, 228
Okayama A, 302
Oldach D, 406
Olivero OA, 477
Olivo N, 498
Omeñaca C, 155
Ongrádi J, 311
Orchi N, 461
Osame M, 200
Othieno R, 294

Pan A, 453
Panretin Gel North American Study Group, 235
Paone D, 83
Paredes R, 132
Park SY, 409
Patterson TA, 477
Pehrson P-O, 445
Pellegrin I, 103
Peña JM, 308
Pérez-Olmeda M, 308
Perlis TE, 83
Perrin L, 174
Peterson D, 39
Pettoello-Mantovani M, 467
Pezzotti P, 65
Phair JP, 386
Piffaretti J-C, 174
Podell M, 10
Poirier MC, 477
Pollard RB, 39
Poretsky L, 146
Pottage J, 39
Puig T, 132
Pyra H, 174

Quinn TC, 19

Rabkin JG, 146
Raboud JM, 260
Rae S, 260
Raghavan SS, 253
Rakik A, 139
Rawal BD, 484
Redfield R, 406
Regazzi MB, 453
Reynes J, 103
Reynolds L, 39
Rezza G, 65
Ricciardulli D, 260
Rich JD, 161
Rockwell R, 83
Rogier H, 228
Romeu J, 132
Ross A, 167
Rossor M, 92
Rouzioux C, 267
Rubinstein A, 467
Rubinstein Y, 467
Ruehlmann DS, 10
Ruiz L, 132
Rusconi S, 101
Rutebemberwa A, 167
Rutkievicz V, 39

Saah AJ, 379
Satten GA, 484
Schaller S, 56
Scheffel JW, 221
Schmidt JB, 247
Schmit J-C, 107
Schooley RT, 333
Schulman KA, 503
Schüpbach J, 174
Schuurman R, 107
Segondy M, 103
Seminari E, 453
Shao Y, 180
Shepherd ME, 19
Simon PA, 490
Simpson N, 1
Sinicco A, 65
Sirera G, 132
Skinhoj P, 325
Slama S, 314
Slikker W Jr, 477
Slutsker L, 71
Smit E, 386
Smith M, 10
Smoller BR, 341
Sobesky G, 401
Solomon L, 272
Song YG, 409
Soriano V, 308
Sotheran JL, 83, 194
Spaulding A, 161
Spirer Z, 467
Sprecher S, 107
Spritzler J, 341
Stamler JS, 1
Standiford HC, 348
Steigbigel RT, 49
Stier E, 247
Stricker RB, 105
Stuver SO, 302
Stuyver L, 107
Suter F, 453, 461
Sydney Primary HIV Infection Study Group, 437

Takenouchi N, 200
Tang AM, 386
Tanuri A, 288

Tao G, 395
Taylor GP, 92
Teglas JP, 267
Teng E, 1
Testa L, 101
Thomas D, 92
Thomas DA, 139
Tinelli C, 453
Tirelli U, 407
Tisdale M, 139
Torres JV, 317
Tosswill JHC, 92
Towe CW, 161
Travers KU, 208
Tremblay C, 430
Trevino RA, 280
Triplett J, 358
Tuldrà A, 132
Tural C, 132
Turett G, 155
Tyner J, 221

Ueno K, 200
Usuku K, 200

Vaccher E, 407
Valentine F, 341
Valenzuela R, 358
Van Laethem K, 107
Van Ranst M, 107
Van Vaerenbergh K, 107
Van Wijngaerden E, 107
Vandamme A-M, 107
Vardinon N, 467
Vella S, 253
Veny A, 132
Viard J-P, 369
Villani P, 453
Viscidi RP, 180
Visonà R, 461
Visscher BR, 386
Vizzard J, 437
Vlahov D, 161

Wabinga H, 379
Wabwire-Mangen F, 379
Wagner B, 235
Walker BD, 208
Walmsley S, 235
Wang Z, 180
Wasserman MP, 272
Weber JN, 92
Weber R, 56
Weidle PJ, 498
Whalen C, 379
Wheeler DA, 253
Whitworth J, 167
Witvrouw M, 107
Wu AW, 461

Yamamura Y, 317
Yang J, 180
Yarrish R, 155
Yoon TY, 409
Young M, 124
Yu EI, 490
Yu X-F, 180
Yust I, 467

Zackin RA, 189
Zaunders J, 437
Zhang X-q, 333
Ziemann R, 221
Zou W, 31
Zwahlen M, 174

STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION (Act of August 12, 1970; Section 3685, Title 39 United States Code). Date of Filing—October 1, 1999. Title of Publication—Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology; Frequency of Issue—15 times per year; Annual Subscription Price—$210.00. Location of Known Office of Publication—12107 Insurance Way, Hagerstown, MD 21740; Location of the Headquarters or General Business Office of Publisher—Lippincott Williams & Wilkins, 227 East Washington Square, Philadelphia, PA 19106; Publisher—Lippincott Williams & Wilkins, 227 East Washington Square, Philadelphia, PA 19106; Editors—W.A. Haseltine, Human Genome Sciences Inc., 9620 Medical Center Drive, Rockville, MD 20850; P.A. Volberding, San Francisco General Hospital, AIDS Activity Division, San Francisco, CA 94110; and W.A. Blattner, Institute of Human Virology, University of Maryland, Baltimore, MD 21201; Managing Editor—Caren P. Erlichman, Lippincott Williams & Wilkins, 227 East Washington Square, Philadelphia, PA 19106; Owner—Lippincott Williams & Wilkins, 227 East Washington Square, Philadelphia, PA 19106; 351 West Camden Street, Baltimore, MD 21201; Wolters Kluwer, US, 345 Hudson Street, New York, NY 10014; Wolters Kluwer nv (owns 100% of stock), Stadouderskade 1, 1054 FS, Amsterdam, The Netherlands; Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities—none. A. Total number of copies printed (*net press run*), average, 2,286, actual, 2,600; B. Paid and/or requested circulation; 1. Outside-county mail subscriptions, average, 1,510, actual 1,383; 2. Paid in-county subscriptions, none; 3. Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, none; 4. Other classes mailed through the USPS, none. C. Total paid and/or requested circulation, average 1,510, actual, 1,383. D. Free distribution by mail (*samples, complimentary, and other free*); 1. Outside-county, average, 327, actual, 374; 2. In-county, none; 3. Other classes mailed through the USPS, none. E. Free distribution outside the mail, none. F. Total free distribution, average, 327, actual, 374. G. Total distribution, average, 1,837, actual, 1,757. H. Copies not distributed, average, 449, actual, 843. I. Total, average, 2,286, actual, 2,600. J. Percent paid and/or requested circulation, average, 82%, actual, 79%. I certify that the statements made by me above are correct and complete. Abbe Nelson, Manager, Periodical Operations, September 23, 1999.

JAIDS Journal of Acquired Immune Deficiency Syndromes
22:521–526 © 1999 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 22, 1999

Subject Index

Abacavir
with inosine monophosphate dehydrogenase-inhibitor mycophenolic acid (letter), 406
phenotypic resistance to, 139
Adherence
to antiretroviral medications in inner-city population, 498
to colposcopy, 247
to protease inhibitor therapy in HIV-infected urban VA medical center patients, 359
Africa
HIV-1 RNA levels in population-based cohort in, 167
HIV-1 subtypes A and B in (letter), 208
immunologic and clinical stages of HIV-1-infected adults and survival in, 509
placental membrane inflammation and mother-to-child transmission of HIV-1 in, 379
sexual behaviors and HIV risk factors of men in, 294
sociodemographic characteristics and HIV-1 subtypes in, 288
AIDS mortality, declining rates of (letter), 312
AIDS progression
dehydroepiandrosterone sulfate and testosterone in, 146
HIV-1 immunologic and clinical stages and, 509
AIDS registries, in statewide non-name-based HIV surveillance system, 272
AIDS serodiagnosis, in incarcerated and reincarcerated women, 161
AIDS vaccine, HIV envelope multivalent, 317
AIDS-defining opportunistic illness, with HIV-related severe immunosuppression, 71
AIDS-related cutaneous Kaposi's sarcoma, topical alitretinoin gel for, 235
AIDS-related HHV-6A, recurrence of (letter), 311
Alitretinoin gel, for AIDS-related Kaposi's sarcoma, 235
Alternative medicine, for HIV-1 infection, 56
Amino acid insertions, in HIV-1 reverse transcriptase, 139
Amplification refractory mutation systems, sensitivity of for HIV-1 resistance, 107
Amprenavir
drug interactions of, 430
phenotypic resistance to, 139
Antiretroviral therapy
adherence to in inner-city population, 498
alternative, 56
factors affecting prescription rates for, 461
HIV-1 reverse transcriptase polymorphisms and, 139
in Italians with known date of HIV seroconversion, 65
primary resistance to, 401
safety and effectiveness of, 39
telomere loss in peripheral blood mononuclear cells during, 445
Antiretroviral-naive patients, didanosine with stavudine in (letter), 103
Anti-tat antibody patterns, in HIV-infected individuals with or without Kaposi's sarcoma, 364
Anxiety, in HIV-1-infected patients, 56
Associated disease, in HTLV-I infection, 92
At-risk groups, HTLV-I/II antibody seroprevalence in blood donors of in Tunisia (letter), 314
AZT
in fetal DNA and fetal tissue after late-term infusion, 477
S-nitrosothiols and, 1

Bacteremia, in HIV-infected patients, 155
Bahia, HIV-1 subtyping in, 288
Binding protein, in HIV-infected patients, 49
Blood donors, HTLV-I/II antibody seroprevalence in (letter), 314
Body cell mass, caloric supplements and, 253
Brazil, HIV-1 subtyping in, 288

Cachexia, insulin-like growth factor and, 49
Caloric supplements, efficacy of in HIV infection, 253
Candidal infection, oral, with HIV protease inhibitors (letter), 105
Caribbean islands, drug resistant mutations in HIV-1 strains in, 401
CCR5
coreceptors of in HIV-1 pathogenesis, 413
phenotypic expressions of, 75
CCR2 alleles, in HIV-1-infected children, 267
$CD4^+$ count
in African population-based cohort, 167
with didanosine and stavudine therapy, 39
in disease progression and survival, 509
early HIV-1 RNA and T-lymphocyte dynamics in, 437
HIV-1-specific cytolytic T-lymphocyte activity and, 19
low-dose oral α-interferon and, 348
with protease inhibitor therapy, 359
CD4 receptors, in HIV-1 pathogenesis, 413
$CD8^+$ T lymphocytes, in interleukin-2-treated HIV infection, 31

CD8+CD38$^-$DR$^-$ phenotype, HIV-1-specific cytolytic T-lymphocyte activity and, 19
Cheju Island, HTLV-I seroprevalence in (letter), 409
Chemokine receptors
  in CCR5 phenotypic expression, 75
  in HIV-1-infected children, 267
Chemokines
  in CCR5 phenotypic expression, 75
  cytotoxic T lymphocytes and, 31
Chemotherapy, HAART after remission induced by (letter), 407
Children, high-dose IV Ig and viral load of (letter), 309
China
  emerging HIV infection subtypes in injection drug users of, 180
  traditional medicine of for HIV-1 infection, 56
Chinese herb therapy, clinical trial of, 56
Chorioamnionitis, mother-to-child transmission of HIV-1 and, 379
Circumcision, sexual behaviors and HIV risk factors and, 294
9-*cis*-retinoic acid, for AIDS-related Kaposi's sarcoma, 235
Clinical stage
  in African population-based cohort, 167
  HIV-1 infection, progression and survival with, 509
Clinical trials
  of caloric supplements in HIV infection, 253
  of low-dose oral α-interferon in HIV-infected patients, 348
  of zidovudine and didanosine therapy versus combined zidovudine, didanosine, and nevirapine, 260
Cohort, initially asymptomatic, HTLV-I infection in, 92
Colposcopy, adherence to among HIV-infected women, 247
Combination antiretroviral therapy
  drug interactions in, 430
  efavirenz, nelfinavir, and stavudine in, 453
  randomized controlled trials comparing, 260
  safety and effectiveness of, 39
  stavudine-related phenotypic resistance in (letter), 101
Coping skills, in HIV-1-infected patients, 56
Cytolytic T-lymphocytes, HIV-1-specific, 19
Cytomegalovirus retinitis, in advance HIV-infected patients treated with protease inhibitors, 228
Cytotoxic T lymphocytes
  in asymptomatic cohort with HTLV-I infection, 92
  in interleukin-2-treated HIV patients, 31

Dehydroepiandrosterone sulfate, in HIV stage and progression, 146
Delayed-type hypersensitivity, to recombinant HIV envelope glycoprotein after immunization, 341
Demographic characteristics, HIV subtypes and, 180
Dendritic cells, in HIV-1 pathogenesis, 413
Depression, in HIV-1-infected patients, 56
Diarrhea, with low-dose oral α-interferon in HIV-infected patients, 348
Didanosine
  in combined therapy trials, 260
  primary resistance to, 401
  safety and effectiveness of, 39
  with stavudine in antiretroviral-naive patients (letter), 103
Dideoxycytidine, primary resistance to, 401
Disease progression
  in children, 267
  dehydroepiandrosterone sulfate and testosterone in, 146
  early HIV-1 RNA and T-lymphocyte dynamics in, 437
  HIV-1 immunologic and clinical stages and, 509
  HIV-related weight loss and, 189
  with protease inhibitors in HIV-infected urban VA medical center patients, 359
  rate of in Italians with known date of HIV seroconversion, 65
Disease stage, protease inhibitor prescription rates for, 461
Diversity, HIV-1 subtyping and, 288
DNA
  amplification assay, for HIV-1 subtypes A and D (letter), 208
  incorporation of AZT in, 477
Drug injection practices, in HIV-1 transmission, 194
Drug interactions, with protease inhibitors and HIV-1 isolates, 430
Drug resistance, novel genotype in, 139
Drug resistance mutations, in HIV-1 strains, 401
Drug users, HIV seroprevalence and related behavior by ethnicity in, 83

Early detection, with HIV enzyme immunoassay testing strategy, 484
Efavirenz
  in combination therapy for HIV-1 infection, 453
  phenotypic resistance to, 139
Enteric microsporidiosis, seasonal variation in (letter), 408
Enzyme immunoassay testing strategy, for early HIV detection, 484
Epidemiology
  in CCR5 phenotypic expression, 75
  of cytomegalovirus retinitis, 228
  of HIV-1 infection in Switzerland, 174
  of HIV risk, 280
Erratum: 'Variations in Inpatient Care for HIV-Related Tuberculosis Patients during a Recent Nosocomial Outbreak of Multidrug-Resistant Tuberculosis' (letter; 21;4:348), 207
Ethnicity, HIV seroprevalence and related behavior by in drug injectors, 83
Ethnography, of injection drug users, 194
EuroSIDA study, response to HAART and survival in, 369
Eye infections, with protease inhibitor treatment, 228

Failure to thrive, in SIV-infected juvenile rhesus monkey, 119
Feline immunodeficiency virus Maryland isolate, frontal lobe neuronal injury in, 10
Fetal DNA, incorporation of AZT in, 477
Fever, with low-dose oral α-interferon in HIV-infected patients, 348
FIV-infected cats, frontal lobe injury in, 10
French West Indies, drug resistant mutations in HIV-1 strains in, 401
Frontal lobe injury, in FIV-infected cats, 10

Gender differences, in skin reactivity to PPD among HTLV-I carriers in Japan, 302

Genetics
in CCR5 phenotypic expression, 75
of HIV-1 infection in Switzerland, 174
Genital tract, HIV-1 RNA in, 124
Genotype, in nucleoside reverse transcriptase inhibitors cross-resistance, 139
Genotypic populations, sensitivity of mutation assays for detecting HIV-1 resistance in, 107
Genotypic resistance, in salvage HAART, 132
Green fluorescent protein, indicator cell assay for HIV-1 isolates based on, 213
Group O envelope recombinant, monoclonal antibodies to, 221
Growth hormones, exogenous, in HIV-infected patients, 49

HAART
as anti-Kaposi's sarcoma therapy after remission (letter), 407
costs of, 503
disease progression, adherence, and response to, 359
rescue combination therapy for HIV-1 after pretreatment with, 453
response to and survival rates, 369
salvage, high-dose saquinavir and ritonavir in, 132
telomere loss in peripheral blood mononuclear cells during, 445
Health care access
factors affecting, 461
HIV patient characteristics and, 503
Health services research, on healthcare costs of hospitalization for HIV infection, 503
Healthcare costs
HIV-infected patient characteristics and, 503
of hospitalization for HIV infection, 503
Hemophilia, CCR5 phenotypic expression and, 75
Hepatitis C virus
CCR5 phenotypic expression and, 75
interferon and ribavirin in HIV-infected patients with (letter), 308
Herbal remedies, in HIV-1 treatment, 56
Herpesvirus, Kaposi's sarcoma-associated, 333
Heteroduplex mobility assay, of HIV-1-seropositive population, 288
Heterosexual transmission, HIV-1 subtype diversity in, 325
HIV
adherence to therapy for in inner-city population, 498
modeling of risk for, 280
multiple subtypes of in heterosexually infected women, 325
prevention of and rates of receiving test results, 395
protease inhibitor prescription rates for stages of, 461
RNA, prognostic significance of early levels of, 437
seropositivity, in incarcerated and reincarcerated women, 161
seroprevalence of
differences in by race among drug injectors, 83
in incarcerated and reincarcerated women, 161
statewide non-name-based system of reporting, 272
transmission of
modeling risk of, 280
mother-to-child (letter), 209
HIV-1
drug-resistant strains of, 401
group O envelope recombinant, monoclonal antibodies to, 221
immunologic and clinical stage and survival of, 509
incidence of in incarcerated and reincarcerated women, 161
isolates
indicator cell assay for, 213
interactions with protease inhibitor combinations, 430
non-B subtypes of, 174
quality of life with, 56
replication of, nitric oxide in, 1
rescue combination therapy for, 453
resistance to, mutation assays for detecting, 107
seroconversion of, early HIV-1 RNA and T-lymphocyte dynamics in, 437
subtypes of
assays for in Uganda (letter), 208
in Chinese injection drug users, 180
diversity of in heterosexually infected women, 325
in South America, 288
transmission of
in injection paraphernalia, 194
monocyte-macrophage lineage cells in, 413
mother-to-child, disease progression and, 267
placental membrane inflammation and, 379
HIV envelope multivalent vaccine, HIV antibodies binding to, 317
HIV immunization, with peptide protein derivative-V3 loop conjugates, 467
HIV plasma viremia, Kaposi's sarcoma with sustained suppression of (letter), 209
HIV protease inhibitors, oral thrush and (letter), 105
HIV-1 reverse transcriptase polymorphisms, in nucleoside reverse transcriptase inhibitor cross-resistance, 139
HIV-1 RNA
in African population-based cohort, 167
in plasma and genital tract sections of HIV-1-infected women, 124
reduction of in salvage HAART, 132
HIV testing
with high-risk sexual behavior, 490
rates of receiving results of, 395
with sensitive/less-sensitive enzyme immunoassay strategy, 484
HIV wasting, predictors of prior to AIDS, 386
Homologous antigen immunization, delayed-type hypersensitivity to rgp160 after, 341
Hospitalization, HIV-infected patient characteristics and, 503
HTLV-I carriers, gender differences in skin reactivity to PPD among, 302
HTLV-I infection
molecular pathologic analysis of tonsil in, 200
prospective study of in initially asymptomatic cohort, 92
HTLV-I seroprevalence, in Cheju Island (letter), 409
HTLV-I/II antibodies, seroprevalence of in blood donors in Tunisia (letter), 314
Human herpesvirus 8 infection, in HIV-1-infected men, 333
Human herpesvirus type 6 variant A, recurrence of with AIDS (letter), 311
Hyperproliferative skin disorders, retinoids for, 235

Hypertension, CCR5 phenotypic expression and, 75
Hypervariable epitope constructs, for AIDS vaccine, 317

Immune activation markers, for HIV-associated weight loss prior to AIDS, 386
Immune reconstitution, with protease inhibitor therapy, 359
Immune response
  with HIV envelope multivalent vaccine, 317
  to HIV-1 immunization with peptide protein derivative-V3 loop conjugates, 467
Immunization
  passive, in HIV-infected patients, 364
  with peptide protein derivative-V3 loop conjugates, 467
Immunoglobulin, high-dose IV, in viral load of HIV-infected children (letter), 309
Immunoglobulin G, anti-tat, in HIV-infected individuals with or without Kaposi's sarcoma, 364
Immunohistochemistry, in HTLV-I infection, 200
Immunointervention
  $CD8^+$ T lymphocyte activation in, 31
Immunologic markers, for HIV-associated weight loss prior to AIDS, 386
Immunologic stage, HIV-1 infection, progression and survival with, 509
Immunosuppression
  HIV-associated weight loss and, 386
  severe HIV-related, opportunistic illness with, 71
Indicator cell assay, for T-cell tropic, macrophage-tropic, and primary HIV-1 isolates, 213
Indinavir
  disease progression, adherence, and response to, 359
  drug interactions of, 430
Injection drug users
  in female prison population, 161
  HIV infections with distinct subtypes among, 180
  HIV seroprevalence and related behavior difference in by ethnicity, 83
  HIV-1 subtyping of, 288
  HIV-1 transmission among, 194
  protease inhibitor prescription rates for, 461
Injection risk, modeling of, 280
Inner-city population, adherence to antiretroviral therapy in, 498
Inosine monophosphate dehydrogenase-inhibitor mycophenolic acid, with abacavir (letter), 406
Insulin resistance, in HIV-infected patient, 49
Insulin-like growth factor system, in HIV-infected patients, 49
Interferon, in HIV-infected patients with chronic hepatitis C (letter), 308
α-Interferon, low-dose oral, multicenter controlled trial of, 348
Interleukin-2, $CD8^+$ T lymphocyte activation and, 31
Italians, disease progression rate and HIV seroconversion in, 65

Japan, gender differences in skin reactivity to PPD among HTLV-I carriers in, 302

Kaposi's sarcoma
  anti-tat antibody patterns with, 364
  HAART therapy after remission in (letter), 407
  in HIV-1-infected men, 333
  with sustained suppression of HIV plasma viremia (letter), 209
  topical alitretinoin gel for, 235
Karnofsky score, low-dose oral α-interferon and, 348
Korean islands, HTLV-I seroprevalence in (letter), 409

Lamivudine
  in combination antiretroviral therapy (letter), 101
  primary resistance to, 401
Latency-associated nuclear antigen (LANA) antibodies, in HIV-1-infected men, 333
Letters to editor, 101, 208, 308, 406
Los Angeles, high-risk sexual behavior in, 490
Lymphocytes
  CCR5 phenotypic expression and, 75
  phenotype of in HTLV-I infection, 92

Macrophage cell lines, in HIV-1 pathogenesis, 413
Macrophage-tropic HIV-1 isolates, indicator cell assay for, 213
Mandatory testing, of incarcerated and reincarcerated women, 161
Martinique, drug resistant mutations in HIV-1 strains in, 401
Mass screening, of incarcerated and reincarcerated women, 161
Medicaid costs, of hospitalization for HIV infection, 503
Mineral supplements, efficacy of in HIV infection, 253
Modeling, of HIV risk, 280
Molecular epidemiology, of HIV-1 infection in Switzerland, 174
Molecular pathologic analysis, of tonsil in HTLV-I-infected patient, 200
Monoclonal antibodies, to HIV-1 group O envelope recombinant, 221
Monocyte cell lines, in HIV-1 pathogenesis, 413
Mortality
  AIDS-related, declining rate of (letter), 312
  bacteremia and predictors of, 155
  immunologic and clinical stage of HIV-1 infection and, 509
Mother-to-child transmission
  HIV-1, CCR2B alleles in, 267
  HIV infection (letter), 209
  placental membrane inflammation and, 379
Multicenter trial, of low-dose oral α-interferon, 348
Multidrug-resistant HIV-1 strains, abacavir with inosine monophosphate dehydrogenase-inhibitor mycophenolic acid for (letter), 406
Multivalent vaccine, antibody binding to, 317
Muslim men, sexual behaviors and HIV risk factors in, 294
Mutation assays, sensitivity of for resistance in mixed HIV-1 genotypic populations, 107
Mycophenolic acid, in combination therapy against multidrug-resistant HIV-1 strains (letter), 406

National Health Interview Survey, on rates of receiving HIV test results, 395
Nelfinavir
  in combination therapy for HIV-1 infection, 453
  drug interactions of, 430

Neuronal injury, with FIV-MD, 10
Neutralizing antibodies, with peptide protein derivative-V3 loop conjugate immunization, 467
Nevirapine, in combined therapy trials, 260
Nitric oxide, in HIV-1 replication, 1
Nucleic acid sequence-based amplification assay, for HIV-1 subtypes A and D (letter), 208
Nucleoside analogues
  rescue combination therapy for HIV-1 after pretreatment with, 453
  resistance to, 401
Nucleoside reverse transcriptase inhibitors, cross-resistance to, 139
Nutritional therapy, efficacy of in HIV infection, 253

Ophthalmologic infections, with protease inhibitor treatment, 228
Opportunistic illness
  HIV-related weight loss stratified by, 189
  unreported AIDS-defining with HIV-related severe immunosuppression, 71
Oral thrush, HIV protease inhibitors and (letter), 105

Passive immunization, anti-tat antibodies and, 364
Pathogenesis, monocyte-macrophage lineage and, 413
Patient-provider relationship, protease inhibitor prescription rates for, 461
Peptide protein derivative-V3 loop conjugates, immunologic response to, 467
Peripheral blood mononuclear cells
  HIV-1 replication in, 1
  telomere loss in, 445
Phenotypic assays, sensitivity of for resistance in mixed HIV-1 genotypic populations, 107
Phylogenetic analysis, of HIV-1 subtypes in South America, 288
Placebo-controlled trial, of Chinese herb therapy for HIV-1 infection, 56
Placental membrane inflammation, mother-to-child transmission of HIV-1 and, 379
Plasma
  HIV-1 RNA in, 124
  RNA viral load measured in (letter), 208
  viral load nadir of with combination therapy, 260
Point mutation assays, sensitivity of for resistance in mixed HIV-1 genotypic populations, 107
Polymerase chain reaction hybridization
  of HIV-1 subtypes in South America, 288
  in HTLV-I infection, 200
Population effect, on antiretroviral treatment of HIV infection, 65
Predictors
  of HIV-associated weight loss prior to AIDS, 386
  of HIV-related weight loss, 189
Pregnancy, transplacental passage of AZT during, 477
Prescription rates, intravenous drug use, patient-provider relationship, and HIV disease stage in, 461
Primates, survival and failure to thrive in SIV-infected juveniles, 119
Prison population, female, HIV prevalence and incidence among, 161
Prognosis
  early HIV-1 RNA and T-lymphocyte dynamics in, 437
  HAART response and, 369
Prostitutes, HIV prevalence and incidence among, 161
Protease inhibitors
  cytomegalovirus retinitis with, 228
  disease progression, adherence, and response to, 359
  factors affecting prescription rates for, 461
  HIV-associated weight loss and, 386
  interactions among combinations of and HIV-1 isolates, 430
  oral thrush and (letter), 105
  primary resistance to, 401
  rescue combination therapy for HIV-1 after pretreatment with, 453
  salvage HAART and, 132
Proviral load, in asymptomatic cohort, 92
Psychosocial measurements, in HIV-1-infected patients, 56
Public health, rates of receiving HIV test results and, 395
Purified protein derivative, gender differences in skin reactivity to among HTLV-I carriers in, 302

Quality of life, alternative therapy and, 56

Race, HIV seroprevalence and related behavior by in drug injectors, 83
Recombinant HIV envelope glycoprotein, delayed-type hypersensitivity to, 341
Recombinant HIV-1 group O envelope protein, monoclonal antibodies to, 221
Rescue therapy, efavirenz, nelfinavir, and stavudine in, 453
Retinitis, cytomegalovirus, in advance HIV-infected patients treated with protease inhibitors, 228
Retinoids, for AIDS-related Kaposi's sarcoma, 235
rgp160, delayed-type hypersensitivity to, 341
Rhesus monkey, late-term AZT infusion and transplacental passage in, 477
Rhode Islands, HIV prevalence and incidence among women prisoners in, 161
Ribavirin, in HIV-infected patients with chronic hepatitis C (letter), 308
Risk behaviors
  in drug injectors by race, 83
  HIV testing and in Los Angeles, 490
  modeling of, 280
Risk factors
  in circumcised and uncircumcised men in Uganda, 294
  in female prison population, 161
  HIV subtypes and, 180
  in populations stratified by opportunistic processes, 189
Risk groups, prognosis and in EuroSIDA study, 369
Ritonavir
  drug interactions of, 430
  with high-dose saquinavir in salvage HAART, 132
RNA, HIV-1, in plasma and genital tract secretions, 124
RNA viral load, measured by branched DNA and nucleic acid sequence-based amplification assays (letter), 208

Salvador, HIV-1 subtyping in, 288
Salvage therapy, high-dose saquinavir and ritonavir in, 132

San Francisco, early HIV enzyme immunoassay testing strategy in, 484
Saquinavir
drug interactions of, 430
with ritonavir in salvage HAART, 132
Seasonal variation, in enteric microsporidiosis among HIV-infected individuals (letter), 408
SEIQoL, in HIV-1-infected patients, 56
Sexual behaviors
in circumcised and uncircumcised men in Uganda, 294
of female prison population, 161
HIV testing and in Los Angeles, 490
Sexual risk, modeling of, 280
Sexually transmitted disease
in circumcised and uncircumcised men in Uganda, 294
in female prison population, 161
Simian immunodeficiency virus, survival and failure to thrive with, 119
S-nitrosothiols, in HIV-1 replication, 1
Sociodemographic characteristics, African, in South American populations, 288
Socioeconomic factors, in hospitalization for HIV infection, 503
South America, HIV-1 subtyping in, 288
Stavudine
in combination therapy for HIV-1 infection, 453
didanosine with in antiretroviral-naive patients (letter), 103
in phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects (letter), 101
safety and effectiveness of, 39
Substance abuse, in female prison population, 161
Subtype chimeric viruses, in heterosexually infected women, 325
Surveillance
of patients with HIV-related severe immunosuppression, 71
statewide non-name-based, 272
Survival
early HIV-1 RNA and T-lymphocyte dynamics in, 437
HAART response and, 369
HIV-1 immunologic and clinical stages and, 509
in Italians with known date of HIV seroconversion, 65
in SIV-infected juvenile rhesus monkey, 119
Switzerland, non-B subtypes in newly diagnosed HIV-1 infections in, 174

T lymphocytes
$CD8^+$, in interleukin-2-treated HIV infection, 31
HIV-1-specific, 19
prognostic significance of early levels of, 437
T-cell tropic HIV-1 isolates, indicator cell assay for, 213
Telomere loss, in peripheral blood mononuclear cells, 445
Testosterone, in HIV stage and progression, 146
Thrush, oral, HIV protease inhibitors and (letter), 105
Tonsil, molecular pathologic analysis of, 200
Triglycerides
long-chain, 253
medium-chain, 253
Tunisia, HTLV-I/II antibody seroprevalence in blood donors of at-risk groups in (letter), 314

U1 cells, HIV-1 replication in, 1
Uganda
HIV-1 subtypes A and B in (letter), 208
immunologic and clinical stages of HIV-1-infected adults and survival in, 509
placental membrane inflammation and mother-to-child transmission of HIV-1 in, 379
sexual behaviors and HIV risk factors in men of, 294
Urban population, adherence to in antiretroviral therapy in, 498
Utilization, HIV patient characteristics and, 503

Vaccine, HIV envelope multivalent, 317
Vertical transmission
HIV infection (letter), 209
placental membrane inflammation and, 379
Veterans Affairs medical centers, disease progression, adherence, and response to protease inhibitors in HIV-infected patients in, 359
Viral load
in African population-based cohort, 167
with combination therapy, 260
dehydroepiandrosterone sulfate and testosterone in, 146
high-dose IV Ig and (letter), 309
HIV-1-specific cytolytic T-lymphocyte activity and, 19
measured by branched DNA and nucleic acid sequence-based amplification assays (letter), 208
with peptide protein derivative-V3 loop conjugate immunization, 467
with protease inhibitor therapy, 359
Viral response, predictors of, 132
Viremia
HIV-associated weight loss and, 386
Kaposi's sarcoma with sustained suppression of (letter), 209
Virologic markers, for HIV-associated weight loss prior to AIDS, 386
Virologic parameters, early HIV-1 RNA and T-lymphocyte dynamics as, 437
Virologic response, to combination therapy, 260
Virus replication, nitric oxide in, 1
Vitamin supplements, efficacy of in HIV infection, 253

Weight loss
caloric supplements for, 253
in populations stratified by opportunistic processes, 189
predictors of prior to AIDS, 386
in SIV-infected juvenile rhesus monkey, 119
Women
adherence to colposcopy among, 247
HIV-1 RNA in plasma and genital tract sections of HIV-1-infected, 124
incarcerated, HIV prevalence and incidence among, 161
World Health Organization clinical staging, in African population-based cohort, 167

Zidovudine
in combined therapy trials, 260
drug interactions of HIV-1 isolates sensitive to, 430
in fetal DNA and fetal tissue after late-term infusion, 477
primary resistance to, 401
stavudine-related phenotypic resistance with pretreatment by (letter), 101